Advertisement
OsseoFit Porous Tissue Matrix is a unique implant manufactured from KenseyNash's proprietary Porous Tissue Matrix technology, which creates foamedscaffolds suited for tissue engineering applications. The OsseoFit PorousTissue Matrix product utilizes several resorbable biomaterials including aproprietary collagen formulation, synthetic polymer and ceramic. This uniquedesign creates a structure that is optimized for specific types of bone voidfilling indications.
Advertisement
"Meeting this milestone is an important accomplishment in achieving fullcommercialization of this novel product and technology, and we are pleased tohave completed this as planned," stated Joseph W. Kaufmann, President and CEOof Kensey Nash Corporation. "We look forward to the product seeing greaterclinical use and to furthering our relationship with Biomet on this excitingtechnology."
About Kensey Nash
Kensey Nash Corporation is a leading medical technology company providinginnovative solutions and technologies for a wide range of medical procedures.The Company provides an extensive range of products into multiple medicalmarkets, primarily in the endovascular, sports medicine and spine markets.Many of the products are based on the Company's significant expertise in thedesign, development, manufacturing and processing of absorbable biomaterials,which has led to partnerships to commercialize technologies. Kensey Nash hasalso commercialized a series of innovative products through its own directendovascular sales force. The Company is known as a pioneer in the field ofarterial puncture closure, as the inventor and developer of the Angio-Seal(TM)Vascular Closure Device, which is licensed to St. Jude Medical, Inc.
Forward-Looking Statements
This press release contains certain statements that are "forward-lookingstatements" within the meaning of Section 27A of the Securities Act of 1933and Section 21E of the Securities Exchange Act of 1934, as amended. Suchstatements are qualified by the inherent risks and uncertainties surroundingfuture expectations generally, and also may materially differ from actualfuture experience involving any one or more of such statements. For Biomet,such risks and uncertainties include our ability to develop and market newproducts and technologies in a timely manner, and the risk factors as setforth from time to time in Biomet's filings with the SEC. For Kensey Nash,such risks and uncertainties include our success in launching endovascularproducts into the marketplace, our dependence on three major customers, andadditional risks as set forth in the Kensey Nash's filings with the SEC. Theinclusion of a forward-looking statement herein should not be regarded as arepresentation by either company that their objectives will be achieved.Neither company undertakes any obligation to publicly update forward-lookingstatements, whether as a result of new information, future events orotherwise.
OsseoFit(TM) is a trademark of Biomet Sports Medicine, Inc.
Porous Tissue Matrix(TM) is a trademark of Kensey Nash Corporation
SOURCE Kensey Nash Corporation
